BioSpace News Archive

CorMedix Inc. today announced financial results for the third quarter and nine months ended September 30, 2022 and provided an update on recent business events.

AnPac Bio-Medical Science Co., Ltd. today announced the resignation of Yuyang Cui as (i) the Co-Chair of the board of directors (the “Board”), and (ii) the Co-Chief Executive Officer, effective from November 7, 2022, and the resignation of Jiawen Kang from the position of (i) a director of the Board, (ii) a member of the audit committee, and (iii) a member of the nominating and corporate governance committee, effective from November 4, 2022.

Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the third quarter ended September 30, 2022.

Appili Therapeutics Inc. today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.

Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience.

NANO-X IMAGING LTD announced results for the third quarter ended September 30, 2022 and provided a business update.

BioCryst Pharmaceuticals, Inc. announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema, including patients who switched from other prophylactic therapies.

Akari Therapeutics, Plc announced the U.S. Food and Drug Administration has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.

Monopar Therapeutics Inc. announced third quarter 2022 financial results and summarized recent program developments.